OncoSec Medical Inc (ONCSQ)

[guti]

Merck does not have a role on the content of the lecture other than the fact that Keytruda is given for free to the doctor who is presenting the lecture. In it he mentions the combination trial which he is in charge of. In case you missed it, I had also mentioned that in the spring of 2015, Vindico Medical Education hosted a number of leading melanoma experts as part of a 2-day international symposium to discuss important advances in Immunotherapy. The monograph, "Updates in Melanoma 2015: Entering a New Therapeutic Era", was created and represents an overview of some of the presentations, focusing on the most recent data on immunotherapy, targeted and intralesional therapies, as well as approaches of combining and sequencing immunotherapeutic and targeted agents. The monograph is what Merck has sponsored in the educational lectures through Vindico.